info@trade-jp.net
menu
News / Blog
May Holidays 2026 - Pay Attention!
Catalog
Rifxima tablets 200 mg for hepatic encephalopathy (hyperammonemia, rifaximin, Xifaxan, Xifaxanta, Normix)
Product Code :
Availability : 8
USD 595.00
General information on Japanese Rifxima tablets 200 mg for hepatic encephalopathy (hyperammonemia, rifaximin, Xifaxan, Xifaxanta, Normix)
Package details: 100 tablets
Manufacturer: ASKA Pharmaceutical Co., Ltd., Japan
Active ingredient: rifaximin (chemical formula C43H51N3O11)
Medical effect: Rifxima tablets are effective for the treatment of hyperammonemia of hepatic encephalopathy.
Contraindications and precautions: do not use for the following categories of patients:
- pregnant women,
- breastfeeding women,
- patients with liver disorder,
- patients with tuberculosis.
If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration of Rifxima tablets 200 mg from Japan for hepatic encephalopathy (hyperammonemia, rifaximin, Xifaxan, Xifaxanta, Normix)
For adults, take 2 tablets (400 mg of the active ingredients) at a time, 3 times a day after meals.
How effective are Rifxima tablets 200 mg from Japan for hepatic encephalopathy (hyperammonemia, rifaximin, Xifaxan, Xifaxanta, Normix)?
Rifxima tablets contain 200 mg of rifaximin, a semisynthetic broad spectrum antibacterial drug. It acts on gut microbiota which produce an ammonia and reduces ammonia production by inhibiting bacterial RNA synthesis. By this, Rifxima tablets improve the symptoms of hepatic encephalopathy.
Who should take Rifxima tablets 200 mg from Japan?
Rifxima tablets reduce mortality in patients with hepatic encephalopathy and alleviate hyperammonemia symptoms. This medicine can be used as an orphan drug. Studies also showed that rifaximin effectively prevents recurrent episodes of hepatic encephalopathy (N. Kimer, A. Krag, L. L. Gluud. “Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy”. Patient Prefer Adherence. 2014, Volume 8, 331–338).
